(NASDAQ: NBTX) Nanobiotix Sa's forecast annual revenue growth rate of -16.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.56%.
Nanobiotix Sa's revenue in 2023 is $7,170,212.On average, 1 Wall Street analysts forecast NBTX's revenue for 2023 to be $1,632,928,206, with the lowest NBTX revenue forecast at $1,632,928,206, and the highest NBTX revenue forecast at $1,632,928,206. On average, 1 Wall Street analysts forecast NBTX's revenue for 2024 to be $1,021,328,774, with the lowest NBTX revenue forecast at $1,021,328,774, and the highest NBTX revenue forecast at $1,021,328,774.
In 2025, NBTX is forecast to generate $93,360,512 in revenue, with the lowest revenue forecast at $93,360,512 and the highest revenue forecast at $93,360,512.